These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22035433)

  • 1. Interleukin 6 inhibition - RA and beyond.
    Woodrick RS; Ruderman EM
    Bull NYU Hosp Jt Dis; 2011; 69(3):225-9. PubMed ID: 22035433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
    Woodrick RS; Ruderman EM
    Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new alternative therapy in dermatology: tocilizumab.
    Koryürek ÖM; Kalkan G
    Cutan Ocul Toxicol; 2016; 35(2):145-52. PubMed ID: 26023856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
    Ding C; Jones G
    Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.
    Alten R; Maleitzke T
    Ann Med; 2013 Jun; 45(4):357-63. PubMed ID: 23650978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
    Kalliolias GD; Liossis SN
    Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A SEVERE CASE OF ADULT ONSET STILLS DISEASE WITH MYOPERICARDITIS, RESISTANT TO TREATMENT WITH TOCILIZUMAB BUT RESPONSIVE TO ANAKINRA.
    Waghmare S; Valecka B; Cairns AP
    Ulster Med J; 2015 May; 84(2):130-2. PubMed ID: 26376493
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease].
    Sekkach Y; Elqatni M; Khattabi AE; Fatihi J; Hammi S; Badaoui M; Elomri N; Mekouar F; Amezyane T; Abouzahir A; Ghafir D
    Presse Med; 2011; 40(7-8):e333-7. PubMed ID: 21550202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin-6 therapy in rheumatoid arthritis.
    Woodrick R; Ruderman EM
    Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Murakami M; Nishimoto N
    Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-IL-6 receptor antibody].
    Nishimoto N
    Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
    [No Abstract]   [Full Text] [Related]  

  • 13. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.
    Park EH; Lee EY; Shin K; Kim HA
    Rheumatol Int; 2020 May; 40(5):791-798. PubMed ID: 31598752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
    Song SN; Yoshizaki K
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adult refractory Still disease with atypical articular manifestations: efficacity of interleukin-6 antagonists (tocilizumab)].
    Rkiouak A; Ennibi K; Zinebi A; Akhouad Y; Reggad A; Rabhi M; Chaari J
    Ann Pharm Fr; 2012 May; 70(3):163-8. PubMed ID: 22655584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
    Furfaro N
    J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction].
    Ljung L; Smeds J; Persson G; Jirlén L; Toolanen G
    Lakartidningen; 2012 Sep 19-26; 109(38):1678-9. PubMed ID: 23094399
    [No Abstract]   [Full Text] [Related]  

  • 19. Tocilizumab in adult-onset Still's disease: the Israeli experience.
    Elkayam O; Jiries N; Dranitzki Z; Kivity S; Lidar M; Levy O; Ablin J; Abu-Shakra M; Savargyl-Maman H; Padova H; Caspi D; Rosner I
    J Rheumatol; 2014 Feb; 41(2):244-7. PubMed ID: 24429168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
    Efthimiou P; Kontzias A; Ward CM; Ogden NS
    Nat Clin Pract Rheumatol; 2007 Jun; 3(6):328-35. PubMed ID: 17538564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.